GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stock

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 4,100 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $93.34, for a total value of $382,694.00. Following the completion of the sale, the chief financial officer owned 248,983 shares in the company, valued at $23,240,073.22. The trade was a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Freidin also recently made the following trade(s):

• On Thursday, August 27th, Aaron Freidin sold 7,900 shares of GRAIL stock. The stock was sold at an average price of $85.01, for a total value of $671,579.00.

GRAIL Stock Up 1.3%

Shares of NASDAQ:GRAL traded up $1.39 on Wednesday, hitting $109.91. 1,075 shares of the company traded hands, compared to its average volume of 945,800. The stock has a 50 day simple moving average of $75.56 and a 200-day simple moving average of $64.31. The company has a market cap of $4.91 billion, a PE ratio of -11.27 and a beta of 3.25. GRAIL, Inc. has a 52 week low of $41.50 and a 52 week high of $118.84.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The company had revenue of $44.69 million for the quarter, compared to analysts’ expectations of $42.39 million. As a group, sell-side analysts anticipate that GRAIL, Inc. will post -10.41 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GRAL. Robert W. Baird increased their price target on shares of GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a report on Tuesday. UBS Group set a $84.00 price target on GRAIL in a report on Thursday, September 17th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a research report on Sunday, September 13th. Mizuho lifted their price objective on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $75.10.

Hedge Funds Weigh In On GRAIL

Several hedge funds and other institutional investors have recently modified their holdings of GRAL. Primecap Management Co. CA purchased a new position in shares of GRAIL in the second quarter worth $148,836,000. Bank of America Corp DE purchased a new position in shares of GRAIL in the 2nd quarter worth approximately $49,389,000. BlackRock Inc. grew its holdings in GRAIL by 20.5% during the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock valued at $244,207,000 after purchasing an additional 608,539 shares during the last quarter. State Street Corp increased its stake in GRAIL by 26.1% in the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock worth $162,859,000 after purchasing an additional 493,621 shares during the period. Finally, Baker BROS. Advisors LP raised its stake in shares of GRAIL by 27.9% during the fourth quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after acquiring an additional 455,208 shares in the last quarter.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.